UBS O'Connor’s Epizyme, Inc EPZM Stock Holding History

UBS O'Connor’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-70,000	Closed	-$1.31M	–	924
2015 Q1	$1.31M	Buy	+70,000	New	+$1.45M	0.03%	348

Other funds holding EPZM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

UBS O'Connor's EPZM Position: Q2 2015 in Review

UBS O'Connor sold out of Epizyme, Inc (EPZM) in Q2 2015, closing a stake of 70,000 shares — an estimated $1.31M sold.

UBS O'Connor first reported a position in EPZM in Q1 2015 and held it in 1 quarter. The position peaked at $1.31M in Q1 2015. 95 funds tracked by Wall St. Rank hold EPZM as of Q2 2015.

UBS O'Connor reported no remaining Epizyme, Inc position as of Q2 2015 after selling out during the quarter.
UBS O'Connor sold 70,000 Epizyme, Inc shares in Q2 2015, an estimated $1.31M.
UBS O'Connor first reported a position in Epizyme, Inc in Q1 2015 and held it in 1 quarter.
UBS O'Connor's Epizyme, Inc position peaked at $1.31M in Q1 2015.
95 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2015.

Based on UBS O'Connor's 13F filing for Q2 2015, filed 13 Aug 2015.